alloSHRINK Expansion Study with FOLFIRI

Celyad Oncology

alloSHRINK BACKGROUND

- CYAD-101 studied with FOLFOX preconditioning chemotherapy
  - Overall well tolerated with no dose limiting toxicities
  - No evidence of graft versus host disease (GvHD)
  - No correlation of safety and efficacy profile with degree of human leukocyte antigen (HLA) typing
- Two patients out of 15 achieved a partial response and nine patients achieved stable disease
  - Disease control rate of 73%
  - Medium progression free survival 3.9 months

EXPANSION TRIAL TREATMENT SCHEDULE



STUDY OVERVIEW

- Enrollment up to 34 patients in two consecutive segments
- Three to six FOLFIRI cycles administered
- CYAD-101 administered every two weeks 48 hours following FOLFIRI preconditioning for a total of three cycles of treatment

PRIMARY OBJECTIVE

- Expansion cohort to confirm the recommended dose of $1x10^9$ cells per infusion

SECONDARY OBJECTIVES

- Safety
- Overall response rate
- CYAD-101 cell kinetics

KEY INCLUSION CRITERIA

- Unresectable mCRC
- Recurrent/progressing disease after at least one metastatic treatment line
- Measurable disease by RECIST version 1.1
- Progressive disease under FOLFIRI treatment within three months prior to study registration

Study registered at NCT03692429

alloSHRINK Expansion Study with FOLFIRI

Celyad Oncology

CYAD-101 OVERVIEW

- Off-the-shelf non-gene edited allogeneic CAR T
- Natural Killer Group 2D (NKG2D) receptor-based CAR
- TCR Inhibitory Molecule (TIM) interferes with T cell receptor (TCR) complex signaling
  - Interference protects patient from risk of GvHD
- All-in-One vector approach
- Single transduction step



Study registered at NCT03692429